The key to prevention of cancer gene therapy rather than traditional medicine
U.S. National Cancer Institute, Eli Lilly and Company announced cancellation of a breast cancer prevention drug tests, also said Novartis to replace the use of genetic techniques for research.
Now clearly can prevent breast cancer drug tamoxifen is its class, but because of endometrial cancer, thrombosis, stroke and other side effects, prevent their wide use, in 1977 as a breast cancer drug Nolvadex initial listing. Eli Lilly and Company Evista is used to treat osteoporosis in postmenopausal women, and reduce the risk of breast cancer, the incidence of high-risk populations. Comprehensive consideration of the Cancer Institute and Novartis Evista Femara after the cost and potential side effects and made the above decision.
Abolition of the drug test was scheduled to begin in June on the health of 12800 postmenopausal women, breast cancer risk assessment. Niederhuber Director and the consultants believe that cancer gene markers into the study more valuable, the association expected that the new test will use the 10-year cost of 100 million U.S. dollars.
Niederhuber in his inaugural speech, the emergence of genetic science into a new era, affecting disease prevention, diagnosis and effective targeted therapy, through DNA screening and bio-technology drugs will reach individualized treatment, and thus an alternative to traditional drug treatment.
Now clearly can prevent breast cancer drug tamoxifen is its class, but because of endometrial cancer, thrombosis, stroke and other side effects, prevent their wide use, in 1977 as a breast cancer drug Nolvadex initial listing. Eli Lilly and Company Evista is used to treat osteoporosis in postmenopausal women, and reduce the risk of breast cancer, the incidence of high-risk populations. Comprehensive consideration of the Cancer Institute and Novartis Evista Femara after the cost and potential side effects and made the above decision.
Abolition of the drug test was scheduled to begin in June on the health of 12800 postmenopausal women, breast cancer risk assessment. Niederhuber Director and the consultants believe that cancer gene markers into the study more valuable, the association expected that the new test will use the 10-year cost of 100 million U.S. dollars.
Niederhuber in his inaugural speech, the emergence of genetic science into a new era, affecting disease prevention, diagnosis and effective targeted therapy, through DNA screening and bio-technology drugs will reach individualized treatment, and thus an alternative to traditional drug treatment.
